The rs2294918 E434K variant modulates patatin‐like phospholipase domain‐containing 3 expression and liver damage
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The patatin‐like phosholipase domain‐containing 3 (PNPLA3) rs738409 polymorphism (I148M) is a major determinant of hepatic fat and predisposes to the full spectrum of liver damage in nonalcoholic fatty liver disease (NAFLD). The aim of this study was to evaluate whether additional PNPLA3 coding variants contribute to NAFLD susceptibility, first in individuals with contrasting phenotypes (with early‐onset NAFLD vs. very low aminotransferases) and then in a large validation cohort. Rare PNPLA3 variants were not detected by sequencing coding regions and intron‐exon boundaries either in 142 patients with early‐onset NAFLD nor in 100 healthy individuals with alanine aminotransferase <22/20 IU/mL. Besides rs738409 I148M, the rs2294918 G>A polymorphism (E434K sequence variant) was over‐represented in NAFLD (adjusted P = 0.01). In 1,447 subjects with and without NAFLD, the 148M‐434E (P < 0.0001), but not the 148M‐434K, haplotype (P > 0.9), was associated with histological NAFLD and steatohepatitis. Both the I148M (P = 0.0002) and E434K variants (P = 0.044) were associated with serum ALT levels, by interacting with each other, in that the 434K hampered the association with liver damage of the 148M allele (P = 0.006). The E434K variant did not affect PNPLA3 enzymatic activity, but carriers of the rs2294918 A allele (434K) displayed lower hepatic PNPLA3 messenger RNA and protein levels (P < 0.05). Conclusions: Rare loss‐of‐function PNPLA3 variants were not detected in early‐onset NAFLD. However, PNPLA3 rs2294918 E434K decreased PNPLA3 expression, lessening the effect of the I148M variant on the predisposition to steatosis and liver damage. This suggests that the PNPLA3 I148M variant has a codominant negative effect on triglycerides mobilization from lipid droplets, mediated by inhibition of other lipases. (H epatology 2016;63:787–798)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Self-citationNonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581 · cited 2×
“Liver fat deposition defines nonalcoholic fatty liver disease (NAFLD), ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), which may progress toward cirrhosis and hepatocellular carcinoma (HCC).((1,2)) Following the epidemics of obesity and metabolic syndrome, NAFLD has become the most frequent liver…”
BackgroundKozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234 · cited 1×
“However, data indicate that further variants in the PNPLA3 region modulate NAFLD risk.((8,25-27)) We hypothesized an enrichment of deleterious PNPLA3 alleles in subjects where a strong genetic component may be assumed.”
BackgroundKryukov, G. V., Pennacchio, L. A., & Sunyaev, S. R. (2007) · The American Journal of Human Genetics · doi:10.1086/513473 · Cited by 598
Romeo, S., Pennacchio, L. A., Fu, Y., Boerwinkle, E., Tybjaerg-Hansen, A., Hobbs, H. H., & Cohen, J. C. (2007) · Nature Genetics · doi:10.1038/ng1984 · Cited by 511 · cited 1×
“Based on in silico predictions((36)) and previous data,((37,41)) we estimated to have a 80% power to detect a 4-fold enrichment in individuals carrying nonsense or missense mutation of PNPLA3 in early NAFLD compared with the general population.”
BackgroundSelf-citationPnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis
Smagris, E., BasuRay, S., Li, J., Huang, Y., Lai, K. V., Gromada, J., Cohen, J. C., & Hobbs, H. H. (2015) · Hepatology · doi:10.1002/hep.27242 · Cited by 379 · cited 1×
“However, these data are consistent with the lack of hepatic phenotype in two independent models of Pnpla3 knockout mouse models, as well as the presence of phenotype in the knock-in mouse model.((42)) A likely mechanism explaining the association with steatosis and liver damage is the accumulation of the 148M PNPLA3 p…”
ResultSpeliotes, E. K., Butler, J. L., Palmer, C. D., Voight, B. F., & Hirschhorn, J. N. (2010) · Hepatology · doi:10.1002/hep.23768 · Cited by 362
Cited by
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Tilg, H., Moschen, A. R., & Roden, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.147 · Cited by 1,002
Genetics and epigenetics of NAFLD and NASH: Clinical impact
Eslam, M., Valenti, L., & Romeo, S. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.003 · Cited by 971
Self-citationA Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease
Abul-Husn, N. S., Cheng, X., Li, A. H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J., Stender, S., Wood, G. C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712191 · Cited by 827
Update on NAFLD genetics: From new variants to the clinic
Trépo, E., & Valenti, L. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.02.020 · Cited by 393
Self-citationNonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Pafili, K., & Roden, M. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101122 · Cited by 330
NAFLD in children: new genes, new diagnostic modalities and new drugs
Nobili, V., Alisi, A., Valenti, L., Miele, L., Feldstein, A. E., & Alkhouri, N. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0169-z · Cited by 309
Self-citationNon-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors
Juanola, O., Martínez-López, S., Francés, R., & Gómez-Hurtado, I. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18105227 · Cited by 302
Trépo, E., Romeo, S., Zucman-Rossi, J., & Nahon, P. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.03.011 · Cited by 291
Self-citationMBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals
Donati, B., Dongiovanni, P., Romeo, S., Meroni, M., McCain, M., Miele, L., Petta, S., Maier, S., Rosso, C., De Luca, L., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04991-0 · Cited by 263
Self-citationNonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
Carlsson, B., Lindén, D., Brolén, G., Liljeblad, M., Bjursell, M., Romeo, S., & Loomba, R. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15738 · Cited by 169
Self-citationNonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?
Valenti, L., Bugianesi, E., Pajvani, U., & Targher, G. (2016) · Liver International · doi:10.1111/liv.13185 · Cited by 171
Self-citationRare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease
Pelusi, S., Baselli, G., Pietrelli, A., Dongiovanni, P., Donati, B., McCain, M. V., Meroni, M., Fracanzani, A. L., Romagnoli, R., Petta, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39998-2 · Cited by 125
Self-citationEn masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH
Kimura, M., Iguchi, T., Iwasawa, K., Dunn, A., Thompson, W. L., Yoneyama, Y., Chaturvedi, P., Zorn, A. M., Wintzinger, M., Quattrocelli, M., et al. (2022) · Cell · doi:10.1016/j.cell.2022.09.031 · Cited by 115
PNPLA3 expression and its impact on the liver: current perspectives
Bruschi, F. V., Tardelli, M., Claudel, T., & Trauner, M. (2017) · Hepatic Medicine: Evidence and Research · doi:10.2147/hmer.s125718 · Cited by 81
PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date
Cherubini, A., Casirati, E., Tomasi, M., & Valenti, L. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.2018418 · Cited by 79
“NAFLD can progress to more worrying conditions such as NASH, cirrhosis and HCC.”
BackgroundInfluentialPrevalence and determinants of liver disease in relatives of Italian patients with advanced MASLD
Pelusi, S., Ronzoni, L., Rondena, J., Rosso, C., Pennisi, G., Dongiovanni, P., Margarita, S., Carpani, R., Soardo, G., Prati, D., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.12.033 · Cited by 16
Self-citation
Metadata
- Authors
- Donati, B., Motta, B. M., Pingitore, P., Meroni, M., Pietrelli, A., Alisi, A., Petta, S., Xing, C., Dongiovanni, P., del Menico, B., Rametta, R., Mancina, R. M., Badiali, S., Fracanzani, A. L., Craxì, A., Fargion, S., Nobili, V., Romeo, S., & Valenti, L.
- Venue
- Hepatology
- Published
- 2016-01-14
- Volume
- 63
- Issue
- 3
- Pages
- 787-798
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2300292045
- Cited by
- 121
- References
- 8
- FWCI
- 7.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.